BRL 26830, (R*,R*)-(±)-methyl-4-(2-[{2-hydroxy-2-phenylethyl} amino]propyl)-benzoate, is a new type of β-adrenoceptor receptor agonist that combines antihyperglycemic and thermogenic properties. In C57BI/KsJ db/db mice, treatment with BRL 26830 (50 mg of the hemifumarate salt/kg diet) decreased blood glucose concentration and normalized water intake. As judged by the normalization of polydipsia, BRL 26830 was effective within 2 days and the effect was maintained throughout a treatment period of up to 11 wk. Treatment of db/db mice with BRL 26830 resulted in an increase in both plasmaand pancreatic insulin concentrations and a partial restoration of first-phase insulin secretion by the isolated, perfused pancreas in response to a high (16.7 mM) glucose pulse. Given acutely, BRL 26830 increased energy expenditure in both fed and fasted db/db mice. When given chronically, BRL 26830 increased significantly the dietary and thermoregulatory component of metabolic rate. It is suggested that the antidiabetic and thermogenic properties of BRL 26830 are linked and that blood glucose acts either directly or indirectly as a substrate for thermogenesis.
Original Contribution|
November 01 1985
Improved Glycemic Control in C57BI/KsJ (db/db) Mice After Treatment with the Thermogenic β-Adrenoceptor Agonist, BRL 26830
M J Carroll;
M J Carroll
Beecham Pharmaceuticals Research Division, Great Burgh, Epsom, Surrey
United Kingdom
Search for other works by this author on:
Carolyn A Lister;
Carolyn A Lister
Beecham Pharmaceuticals Research Division, Great Burgh, Epsom, Surrey
United Kingdom
Search for other works by this author on:
M V Sennitt;
M V Sennitt
Beecham Pharmaceuticals Research Division, Great Burgh, Epsom, Surrey
United Kingdom
Search for other works by this author on:
N Stewart-Long;
N Stewart-Long
Beecham Pharmaceuticals Research Division, Great Burgh, Epsom, Surrey
United Kingdom
Search for other works by this author on:
M A Cawthorne
M A Cawthorne
Beecham Pharmaceuticals Research Division, Great Burgh, Epsom, Surrey
United Kingdom
Search for other works by this author on:
Address reprint requests to Dr. M. A. Cawthorne at the above address.
Diabetes 1985;34(11):1198–1204
Article history
Received:
December 14 1984
Revision Received:
April 29 1985
PubMed:
2864298
Citation
M J Carroll, Carolyn A Lister, M V Sennitt, N Stewart-Long, M A Cawthorne; Improved Glycemic Control in C57BI/KsJ (db/db) Mice After Treatment with the Thermogenic β-Adrenoceptor Agonist, BRL 26830. Diabetes 1 November 1985; 34 (11): 1198–1204. https://doi.org/10.2337/diab.34.11.1198
Download citation file: